Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul;13(7):e240044.
doi: 10.57264/cer-2024-0044. Epub 2024 May 29.

First in class, best in class or a wild card: who will dominate the anti-obesity medication market?

Emma Collins  1 , Alice Beattie  1 , Sreeram V Ramagopalan  1   2 , Jonathan Pearson-Stuttard  1
Affiliations
Editorial

First in class, best in class or a wild card: who will dominate the anti-obesity medication market?

Emma Collins et al. J Comp Eff Res. 2024 Jul.
No abstract available

Keywords: AOM; AOM market; GLP-1 agonist; anti-obesity; anti-obesity medication; best-in-class; first-in-class; market access; weight loss.

PubMed Disclaimer

Conflict of interest statement

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.. Hazard ratios for individuals with BMI of 45 kg/m2 relative to a stable BMI of 30 kg/m2 and prevalence of obesity related complications for individuals between BMI 40 kg/m2 and 70 kg/m2 (class III).
Prevalence is shown as the proportion of participants in the study with the obesity related complication [3,4]. T2DM: Type 2 diabetes mellitus.
Figure 2.
Figure 2.. Current GLP-1 agonist anti-obesity medications and expected upcoming anti-obesity medications.
Information from https://clinicaltrials.gov/ and/or company websites [13–34]. SC: Subcutaneaous.
See this image and copyright information in PMC

References

    1. World Obesity Day Atlases. Obesity Atlas 2023. World Obesity Federation Global Obesity Observatory. Available from: https://data.worldobesity.org/publications/?cat=19
    1. Mohajan D, Mohajan HK. Obesity and its related diseases: a new escalating alarming in global health. J. Innov. Med. Res. 2, 12–23 (2023).
    1. Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int. J. Obes. 45, 1249–1258 (2021). - PMC - PubMed
    1. Evans M, de Courcy J, de Laguiche E et al. Obesity-related complications, healthcare resource use and weight loss strategies in six European countries: the RESOURCE survey. Int. J. Obes. 47, 750–757 (2023). - PMC - PubMed
    1. WHO MiNDbank - Sozialgesetzbuch (SGB) Fünftes Buch (V) Gesetzliche Krankenversicherung (Social Code (SGB) Book Five (V) Statutory Health Insurance). Available from: https://extranet.who.int/mindbank/item/2266

Publication types

Substances

LinkOut - more resources